FDA asks panel to weigh benefits, risks of Tysabri
MarketWatch - USA
... site Monday, the FDA said it will ask the advisory committee to "reassess the risks and benefits of natalizumab (the generic name of the Tysabri) and advise ...
See all stories on this topic

US FDA staff-Questions remain on Biogen MS drug
Reuters - USA
... O: Quote, Profile, Research) and Elan Corp.'s (ELN.I: Quote, Profile, Research) (ELN.N: Quote, Profile, Research) multiple sclerosis drug Tysabri may raise the ...
See all stories on this topic

Tysabri® Two-Year Phase III Multiple Sclerosis Clinical Trial ...
Medical News Today (press release) - UK
... BIIB) and Elan Corporation, plc (NYSE: ELN) announced today that two-year results from the two Phase III clinical trials evaluating TYSABRI® (natalizumab) for ...